导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 13.95% | 661/4773 |
| 近一周 | -0.27% | 999/5465 |
| 近一月 | -4.63% | 3366/5421 |
| 近一季 | -9.38% | 3557/5231 |
| 近半年 | 13.36% | 419/4920 |
| 近一年 | 13.63% | 872/4394 |
| 近两年 | 82.12% | 819/2954 |
| 近三年 | 49.74% | 558/2253 |
| 成立以来 | -7.77% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.35% 3602/4961 |
47.73% 645/5312 |
- - |
- - |
| 2025 | 28.76% 1454/4813 |
1.09% 1704/3635 |
-1.05% 3099/4076 |
33.61% 1032/4524 |
-3.65% 3314/4813 |
| 2024 | 7.77% 1620/3463 |
-2.97% 1460/2808 |
-1.44% 1063/3014 |
14.08% 2049/3129 |
-1.22% 1628/3463 |
| 2023 | -11.77% 1425/2656 |
6.48% 683/2280 |
-7.69% 1890/2385 |
-4.99% 1266/2515 |
-5.52% 1383/2655 |
| 2022 | -23.32% 1127/2207 |
-18.58% 1355/1919 |
9.77% 269/2016 |
-15.86% 1356/2113 |
1.97% 1073/2208 |
| 2021 | -1.53% 807/1822 |
-6.31% 993/1255 |
12.58% 325/1330 |
-8.66% 1148/1466 |
2.21% 658/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 天弘国证消费100指数增强发起A VS. 长安沪深300非周期A(740101) |